Ellagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1
5 affiliations
- 1Graduate School of Tianjin University of Traditional Chinese Medicine
- 2Department of Pathology, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
- 3Department of Pharmacy, Tianjin Union Medical Center, The First Affiliated Hospital of Nankai University
- 4Key Laboratory of Molecular Microbiology and Technology, Ministry of Education, TEDA Institute of Biological Sciences and Biotechnology, Nankai University
- 5Ningxia Medical University General Hospital
Abstract
Introduction: Drug resistance in colorectal cancer frequently leads to chemotherapy failure. The application of small-molecule compounds to enhance chemotherapy efficacy has become a common therapeutic strategy. Ellagic acid, a natural polyphenol in plants, is abundantly contained in herbal medicines used for adjuvant chemotherapy against colorectal cancer. Nevertheless, the regulatory effect of ellagic acid on oxaliplatin-based chemotherapy remains unclear.
Methods: Cell Counting Kit-8 and colony formation assays were used to evaluate the efffcacy of the combination of ellagic acid and oxaliplatin. Network pharmacology, Human Phospho-Kinase Array, co-immunoprecipitation and thermal shift assay were used to screen potential targets of ellagic acid in chemotherapy sensitization. Transfection of overexpression plasmids and shRNAs against these targets was performed to verify the underlying mechanism. Tumor tissues derived from colorectal cancer patients were used to establish PDX models for in vivo experiments. All cells and tissues used in this study have wild-type TP53 .
Results: Cellular experiments demonstrated that ellagic acid exerts a synergistic effect with oxaliplatin. Target screening revealed that ellagic acid inhibits Wip1, thereby upregulating p53 and resulting in the synergistic anti-tumor effect. Further studies demonstrated that ellagic acid interacts to ATM and suppresses ATM phosphorylation, thereby downregulating Wip1 via the ATM/ AMPK/HIPK2 signaling pathway. Data from FOLFOX chemotherapy indicated that high Wip1 expression correlates with poor prognosis. PDX models demonstrated that ellagic acid enhances the therapeutic efficacy of oxaliplatin, particularly in tumors with high Wip1 expression.
Discussion: Our findings indicate that ellagic acid enhances the antitumor efficacy of oxaliplatin in colorectal cancer with wild-type TP53 and high Wip1 expression.
Related
- Lipid metabolism mediating oxaliplatin resistance in colorectal cancer
- IRF4 transcriptionally activates CD36 to regulate glycolysis and suppress oxaliplatin resistance in colorectal cancer
- Exogenous carnitine can modulate oxaliplatin sensitivity in colorectal cancer cells in vitro
- Synergistic induction of pyroptosis-like cell death in colorectal cancer cells by norcantharidin and low-dose oxaliplatin promotes M1 macrophage polarization
- XDH Inhibits the Progression of Colorectal Cancer via Regulating Ferritinophagy Signaling.
BibTeX
@article{zhao2026ellagic,
title = {{Ellagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1}},
author = {Ying Zhao and Mingqian Ma and Siqi Han and Jingxian Hu and Xi Guo and Wei Wang and Shudan Liu and Zhenying Zhao and Yaya Qiao and Yijia Wang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1944826},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1944826/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Ellagic acid promoted efficacy of oxaliplatin on wild-type TP53 colorectal cancer via regulating ataxia-telangiectasia mutated protein kinase and Wip1
AU - Ying Zhao
AU - Mingqian Ma
AU - Siqi Han
AU - Jingxian Hu
AU - Xi Guo
AU - Wei Wang
AU - Shudan Liu
AU - Zhenying Zhao
AU - Yaya Qiao
AU - Yijia Wang
PY - 2026
DA - 2026/10/15
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1944826
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1944826/full
AB - Introduction: Drug resistance in colorectal cancer frequently leads to chemotherapy failure. The application of small-molecule compounds to enhance chemotherapy efficacy has become a common therapeutic strategy. Ellagic acid, a natural polyphenol in plants, is abundantly contained in herbal medicines used for adjuvant chemotherapy against colorectal cancer. Nevertheless, the regulatory effect of ellagic acid on oxaliplatin-based chemotherapy remains unclear. Methods: Cell Counting Kit-8 and colony formation assays were used to evaluate the efffcacy of the combination of ellagic acid and oxaliplatin. Network pharmacology, Human Phospho-Kinase Array, co-immunoprecipitation and thermal shift assay were used to screen potential targets of ellagic acid in chemotherapy sensitization. Transfection of overexpression plasmids and shRNAs against these targets was performed to verify the underlying mechanism. Tumor tissues derived from colorectal cancer patients were used to establish PDX models for in vivo experiments. All cells and tissues used in this study have wild-type TP53 . Results: Cellular experiments demonstrated that ellagic acid exerts a synergistic effect with oxaliplatin. Target screening revealed that ellagic acid inhibits Wip1, thereby upregulating p53 and resulting in the synergistic anti-tumor effect. Further studies demonstrated that ellagic acid interacts to ATM and suppresses ATM phosphorylation, thereby downregulating Wip1 via the ATM/ AMPK/HIPK2 signaling pathway. Data from FOLFOX chemotherapy indicated that high Wip1 expression correlates with poor prognosis. PDX models demonstrated that ellagic acid enhances the therapeutic efficacy of oxaliplatin, particularly in tumors with high Wip1 expression. Discussion: Our findings indicate that ellagic acid enhances the antitumor efficacy of oxaliplatin in colorectal cancer with wild-type TP53 and high Wip1 expression.
SN - 1663-9812
ER -